Advanced search

News (404)

Resonac Holdings Corporation - Changes in Representative Director and Other Members of Management	11-22	AQ
Astellas and Roche Diabetes Care Japan ink partnership agreement to develop and commercialize integrated diabetes self-management solution with BlueStar®	29/03/23	PR
Phase 3 Study Shows XTANDI® (enzalutamide) plus Leuprolide Significantly Improves Metastasis-Free Survival in Men with Nonmetastatic Prostate Cancer	23/03/23	AQ
Astellas Announces Positive Findings from Phase 3 GLOW Trial of Zolbetuximab during March ASCO Plenary Series	22/03/23	AQ
Astellas Announces Phase 3 China ARCHES Study of XTANDI Meets Primary Endpoint	14/03/23	AQ
Results from Astellas Pivotal Phase 3 SKYLIGHT 1 Study of Fezolinetant for Vasomotor Symptoms Due to Menopause Published in The Lancet	14/03/23	AQ
Astellas and Seagen Announce China's National Medical Products Administration Accepts Biologics License Application for Enfortumab Vedotin	10/03/23	AQ
Astellas and Seagen Announce China’s National Medical Products Administration Accepts Biologics License Application for Enfortumab Vedotin in Certain Patients with Locally Advanced or Metastatic Urothelial Cancer	09/03/23	BU
Astellas and BMT CTN Announce Topline Results from Phase 3 MORPHO Trial of Gilteritinib	09/03/23	PR
Astellas Announces Update on Preliminary Safety and Efficacy Data from FORTIS Study of Investigational AT845 in Adults with Late-Onset Pompe Disease	23/02/23	AQ
Mitsubishi Chemical : Announcement of Winning the 5th Japan Open Innovation Prize "Minister of Environment Award" "Practical Use of Environmentally Friendly Biomass-based Plastic for Blister Packages"NEW	22/02/23	PU
Astellas Provides Update on Fezolinetant New Drug Application in U.S.	19/02/23	PR
Transcript : Astellas Pharma Inc. - Special Call	17/02/23
Astellas and Bayer announce management changes	10/02/23	AQ
Astellas Commits to Achieve Net Zero Greenhouse Gas Emissions by 2050	09/02/23	PR
Astellas Announces Change of President and CEO and Management Structure	06/02/23	PR
Astellas Pharma Inc. Announces Executive Changes	06/02/23	CI
Astellas Pharma Inc. Announces CEO Changes, Effective April 1, 2023	06/02/23	CI
Astellas Transfers MYCAMINE Product Worldwide	24/01/23	AQ
Astellas Transfers MYCAMINE® Product Worldwide	23/01/23	PR
Astellas Announces Hold Lifted by FDA on FORTIS Clinical Trial of AT845 Investigational Treatment for Adult Patients with Late-Onset Pompe Disease	23/01/23	AQ
Astellas Receives SBTi Approval for Revised Science-Based Climate Goals to Reduce Greenhouse Gas Emissions	19/01/23	PR
Twist Bioscience and Astellas Enter into Multitarget Antibody Discovery Research Collaboration	09/01/23	BU
Astellas, Eisai, Daiichi Sankyo and Takeda Agree to Collaborate to Reduce Environmental Burden in the Field of Pharmaceutical Packaging	22/12/22	PR
Astellas, Seagen and Merck Announce FDA Acceptance of Supplemental Biologics License Applications for PADCEV (enfortumab vedotin-ejfv) with KEYTRUDA (pembrolizumab) for the First-Line Treatment of Certain Patients	21/12/22	AQ
Astellas Announces Zolbetuximab Meets Primary Endpoint in Phase 3 GLOW Trial as First-Line Treatment in Claudin 18.2 Positive, HER2-negative Locally Advanced Unresectable or Metastatic Gastric and Gastroesophageal Junction Cancers	16/12/22	AQ
Astellas and MBC BioLabs Announce 2022 Future Innovator Prize Awarded to Bespoke Biotherapeutics and Cellinfinity Bio	13/12/22	PR
Transcript : Astellas Pharma Inc. - Special Call	09/12/22
Astellas Announces Zolbetuximab Meets Primary Endpoint in Phase 3 SPOTLIGHT Trial as First-Line Treatment in Claudin 18.2 Positive, HER2-Negative Locally Advanced or Metastatic Gastric and Gastroesophageal Junction Cancers	17/11/22	AQ
Transcript : Astellas Pharma Inc., Q2 2023 Earnings Call, Oct 31, 2022	31/10/22
Astellas and Taysha Gene Therapies Announce Strategic Investment to Support Development of Taysha's AAV-based Gene Therapy Programs	25/10/22	PR
Astellas and Taysha Gene Therapies Announce Strategic Investment to Support Development of Taysha’s AAV-based Gene Therapy Programs	25/10/22	AQ
Astellas to Present Findings from Phase 3 Long-Term Safety Study of Fezolinetant in Oral Session at The North American Menopause Society 2022 Annual Meeting	12/10/22	AQ
Astellas and Pantherna Enter into a New Technology Evaluation Agreement for Research with Expanded Target Organ to Generate mRNA-Based Regenerative Medicine Programs Using Direct Reprogramming	04/10/22	PR
European Medicines Agency Accepts Astellas Marketing Authorization Application for Fezolinetant	30/09/22	AQ
European Medicines Agency Accepts Astellas' Marketing Authorization Application for Fezolinetant	30/09/22	PR
Astellas and MBC BioLabs Announce Astellas Future Innovator Prize to Help Biotech Start-ups Accelerate Early Drug Discovery and Research Efforts	20/09/22	AQ
Seagen, Astellas and Merck Announce Results of Clinical Trial Investigating PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) and PADCEV as Monotherapy in First-Line Advanced Urothelial Cancer	12/09/22	BU
Astellas Announces Topline Results from Phase 3 Long-Term Safety Study of Fezolinetant in Mainland China	05/09/22	PR
U.S. FDA Accepts Astellas' New Drug Application for Fezolinetant	18/08/22	PR
Astellas Pharma : Financial Results (Q1/FY2022)	01/08/22	PU
Astellas and Seagen Announce Positive Topline Results For PADCEV (enfortumab vedotin-ejfv) with KEYTRUDA (pembrolizumab) as First-Line Treatment for Advanced Urothelial Cancer	27/07/22	AQ
Seagen : and Astellas Announce Positive Topline Results For PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) as First-Line Treatment for Advanced Urothelial Cancer - Form 8-K	26/07/22	PU
Astellas Pharma : and Seagen Announce Positive Topline Results For PADCEV with KEYTRUDA as First-Line Treatment for Advanced Urothelial Cancer	26/07/22	PU
Seagen and Astellas Announce Positive Topline Results For PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) as First-Line Treatment for Advanced Urothelial Cancer	26/07/22	BU

1234NextSee all

Insiders

Kenji Yasukawa

Presently, Kenji Yasukawa occupies the position of President, CEO & Representative Director at Astellas Pharma, Inc. and Chairman & Chief Executive Officer for Astellas Pharma SpA, Chief Executive Officer of Astellas Pharma US, Inc. and President & Chief Executive Officer at Astellas US LLC (which are all subsidiaries of Astellas Pharma, Inc.). In his past career he occupied the position of Global Head-Urology Therapeutic Areas at Astellas Pharma Global Development, Inc.

Shuichi Yasukawa

Shuichi Yasukawa currently works at N.E.
Chemcat Corp., as Director and Sumitomo Metal Mining Co. Ltd., as Head-HR Development, Public & Investor Relations from 2019.

Akihiko Yasukawa

Tomokatsu Yasukawa

Tomokatsu Yasukawa currently works at Neturen Co., Ltd., as Director & General Manager-Administration from 2014 and Neturen Meinan Co., Ltd., as President & Representative Director from 2011.

Koichiro Yasukawa

Koichiro Yasukawa worked as an Auditor at Shinnihon Corp.
from 2003 to 2016.

Atsushi Yasukawa

Seiichiro Yasukawa

Seiichiro Yasukawa currently works at STI Sanoh India Ltd., as Director from 2015.

Ryuji Yasukawa

Kazuyoshi Yasukawa

Takuji Yasukawa

Mr. Takuji Yasukawa is Executive Officer at Kao Corp.

No results for this search